For the first time, Biogen released details Thursday on how it intends to prove that its by turns celebrated and maligned drug Aduhelm can actually slow the decline of patients with Alzheimer’s, as…
For the first time, doctors will have a drug to combat acute graft-versus-host disease — a dangerous side effect of stem cell transplants in which donor cells attack the recipient — before it occurs.…
The Covid-19 pandemic has been an extremely profitable time for Pfizer, and the massive drugmaker is using that leverage to advance its portfolio writ large. Now, Pfizer’s emerging gene therapy biz…
Two weeks ago, Valneva pushed back against a study that found its candidate, VLA2001, was the only one out of seven tested vaccines that didn’t significantly boost protection when given to volunteers…
After years of developing its gene therapy for cancer on the outskirts of biotech, Genenta has landed on Nasdaq as the first Italian biotech on the American exchange. Genenta’s IPO is small compared…
Novo Nordisk scored a pair of double wins the last couple years with the approval of two different forms of semaglutide, the company’s newest blockbuster product line. Now, Novo is setting aside a…
Australian firm CSL paid a steep price earlier this week for Vifor Pharma and its pipeline of iron and kidney drugs. Looking to ensure it starts its next phase as battle-ready as possible, Vifor will…
Horizon Therapeutics is no stranger to swinging deals, and on Thursday the Irish biotech grabbed itself a new partner to help build out its early-stage pipeline. In a collaboration expected to bring…
Eli Lilly and Merck are piling on to fund AI drug discovery company Verge Genomics, which has a fresh $98 million to continue its tech-enabled approach to finding new medicines.
A new company emerged from stealth this morning in San Francisco Bay, and it’s one focused on research technology. Nodexus, a bio company that develops automated live cell characterization and…
